Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-19

Clinical Trial Update: Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD [Phase 2]

View source ↗

Summary

Phase 2 trial update for Humacyte’s human acellular vessel (HAV) used in femoro-popliteal bypass for peripheral artery disease; the study has completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Human Acellular Vessel (HAV)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Peripheral Artery Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-12-19